Enfusion, Inc. (NYSE:ENFN) Short Interest Down 17.7% in August

Enfusion, Inc. (NYSE:ENFN) was the target of a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 1,900,000 shares, a decline of 17.7% from the August 15th total of 2,310,000 shares. Approximately 3.9% of the company’s stock are sold short. Based on an average daily volume of 374,600 shares, the days-to-cover ratio is presently 5.1 days.

Enfusion Stock Performance

NYSE ENFN opened at $8.73 on Wednesday. Enfusion has a 52 week low of $7.52 and a 52 week high of $10.45. The stock’s 50 day moving average price is $8.52 and its two-hundred day moving average price is $8.87. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of 291.00, a PEG ratio of 2.23 and a beta of 0.90.

Enfusion (NYSE:ENFN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $49.46 million during the quarter, compared to the consensus estimate of $50.27 million. Enfusion had a return on equity of 6.17% and a net margin of 1.98%. On average, equities research analysts forecast that Enfusion will post 0.07 EPS for the current year.

Insider Activity at Enfusion

In related news, insider Bronwen Bastone sold 18,241 shares of the firm’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $8.11, for a total transaction of $147,934.51. Following the sale, the insider now directly owns 198,913 shares in the company, valued at $1,613,184.43. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 36.44% of the stock is owned by insiders.

Hedge Funds Weigh In On Enfusion

Hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC acquired a new position in Enfusion during the first quarter worth $44,000. RiverPark Advisors LLC bought a new position in shares of Enfusion in the 2nd quarter valued at about $68,000. Arizona State Retirement System acquired a new position in shares of Enfusion during the 2nd quarter worth about $86,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Enfusion in the 1st quarter valued at about $102,000. Finally, Quadrature Capital Ltd acquired a new stake in Enfusion in the 1st quarter valued at about $109,000. Institutional investors own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.